Stockscreener 앱 받기
119.41
8.28%
9.13
시장 영업 전:
119.57
0.16
+0.13%
Gilead Sciences Inc 주식(GILD)의 최신 뉴스
Gilead ends Novo Nordisk-partnered liver disease candidate - medwatch.com
Gilead Sciences soars on strong HIV drug sales - medwatch.com
Gilead Sciences Is Closing In on an All-Time High. The Case for More Upside. - Barron's
Gilead Sciences’ Twice-Yearly HIV Prevention Drug Recommended for Approval by European Medicines Agency - Insider Monkey
Gilead Sciences' Strategic Momentum with Yeztugo and HIV Portfolio Growth: A Cornerstone for Long-Term Value Creation - AInvest
Gilead Sciences (GILD) Touches New Record High as 10 Analysts Turn Bullish - MSN
Gilead Sciences Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Gilead Sciences, Inc. (NASDAQ:GILD) Q2 2025 Earnings Call Transcript - Insider Monkey
Gilead Sciences (GILD) Rises on Raised 2025 Guidance and $6B Buyback Is Its Outlook Reinvigorated? - simplywall.st
Gilead trims assets partnered with Novo Nordisk, Arcus from pipeline - FirstWord Pharma
Gilead Sciences Surges 8.28% On Bullish Breakout With Heavy Volume - AInvest
Earnings Season Boosts Confidence: Gilead and Expedia Lead Strong Corporate Results - FinancialContent
These Stocks Moved the Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Gilead, Peloton, and More - Barron's
Why Gilead Stock Surged 8%, Flirting With A Breakout - Investor's Business Daily
Gilead Sciences shares soar; analysts lift targets on HIV strength and Yeztugo outlook - Invezz
Gilead Rallies: Bullish Surge Continues! - timothysykes.com
Gilead Sciences stock price target raised to $140 from $126 at BofA - Investing.com Australia
NASDAQ Index, SP500, Dow Jones Forecasts – NASDAQ Gains Ground As Gilead Sciences Soars 8% - FXEmpire
Gilead Sciences jumps after Q2 beat; Truist upgrades to Buy - MSN
Gilead Sciences’ Yeztugo Projected to Reach $5 Billion in Global Sales by 2031 - geneonline.com
Earnings Season Highlights: Gilead Sciences and Expedia Group Post Strong Results - FinancialContent
Gilead Sciences Inc (GILD) share price, Expedia Group Inc (EXPE) stocks make record-breaking jump. Details - The Economic Times
Gilead’s Yeztugo sales “ahead of expectations” following launch - Yahoo Finance
Gilead Sciences’ Breast Cancer Study: A Potential Game-Changer in Oncology? - TipRanks
Why Is Gilead Sciences (GILD) Stock Rocketing Higher Today - Yahoo Finance
Gilead and Arcus Advance Promising Colorectal Cancer Study - TipRanks
Gilead Sciences Stock Surges 9% on Strong Q2 Earnings - AInvest
Gilead and Arcus Biosciences’ Promising Study on Advanced Gastrointestinal Cancers - TipRanks
Gilead culls Novo-partnered MASH candidate and 2 cancer assets - Fierce Biotech
Amid excitement over Yeztugo, Gilead sees continued erosion of CAR-T sales - Fierce Pharma
Gilead Sciences Up Over 8%, on Track for Highest Close Since June 2015 — Data Talk - Morningstar
Why Is Gilead Sciences Stock Surging Friday?Gilead Sciences (NASDAQ:GILD) - Benzinga
Gilead's Optimistic Relaxed CAR T Safety Monitoring Could Help Sluggish Yescarta, Tecartus Q2 Sales - Precision Medicine Online
Gilead Sciences: Is There Momentum to Sustain Market Buzz? - StocksToTrade
Shareholders strongly echo Gilead’s successful quarter claims - The Pharma Letter
Gilead Sciences stock price target raised to $98 from $96 at RBC Capital - Investing.com
Truist Securities Upgrades Gilead Sciences to Buy From Hold, Hikes Price Target to $127 From $108 - MarketScreener
UBS Raises Price Target on Gilead Sciences to $112 From $108, Maintains Neutral Rating - MarketScreener
Gilead Sciences stock price target raised to $115 from $110 at TD Cowen - Investing.com Canada
Gilead Sciences Reports Strong Q2 Earnings, Beats Wall Street EstimatesNews and Statistics - IndexBox
Baird Adjusts Price Target on Gilead Sciences to $108 From $100, Maintains Neutral Rating - MarketScreener
JPMorgan Adjusts Price Target on Gilead Sciences to $135 From $130, Maintains Overweight Rating - MarketScreener
BMO Capital Adjusts Price Target on Gilead Sciences to $130 From $120, Maintains Outperform Rating - MarketScreener
Gilead Stock Showered With Upgrades, Price Target Hikes After Upbeat Q2, Guidance Lift: Retail’s Turned Exuberant - Stocktwits
Goldman Sachs Adjusts Price Target on Gilead Sciences to $105 From $100, Maintains Neutral Rating - MarketScreener
Gilead Confident in PrEP Franchise Even Amid Preventive Task Force Uncertainties - BioSpace
Executives On The Move: Changes At The Top At Novo Nordisk Plus Other New CEOs - insights.citeline.com
Truist Securities upgrades Gilead Sciences stock to Buy on HIV strength - Investing.com Canada
Gilead Sciences stock price target raised to $112 from $108 at UBS - Investing.com Canada
Stock Movers: LMT, Monster, Gilead - Bloomberg.com
Street View: Optimistic about launch of Gilead's twice-yearly HIV prevention shot - TradingView
Gilead Sciences (GILD) Soars 3.73% on Strong Q2 Earnings - AInvest
Gilead lifts 2025 forecast as HIV treatment sales strengthen - MSN
These Stocks Are Moving Most Today: Trade Desk, Expedia, Pinterest, Twilio, Gilead Sciences - MSN
Gilead Sciences: Strong Q2 Performance and Promising Outlook Drive Buy Rating - TipRanks
Gilead Q225 slides: HIV strength drives guidance raise, oncology pipeline advances - Investing.com
Gilead posts Q2 beat, raises full-year outlook on HIV drugs demand By Investing.com - Investing.com South Africa
Gilead posts Q2 beat, raises full-year outlook on HIV drugs demand - Investing.com Canada
Gilead HIV Treatment and Prevention Portfolio Has a Long Patent Life, Contributing to a Wide Moat - Morningstar
Gilead Sciences Inc (GILD) Q2 2025 Earnings Call Highlights: Str - GuruFocus
Gilead Sciences Announces Second Quarter 2025 Financial Results - BioSpace
Gilead Sciences Reports Strong Q2 2025 Results - TipRanks
Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight - GuruFocus
Gilead Sciences: Strong Financial Performance and Positive Outlook Justify Buy Rating - TipRanks
Gilead's Q2 2025: Unpacking Contradictions in Yeztugo Launch, Tariff Impacts, and PrEP Market Dynamics - AInvest
Gilead Sciences Q2: The New Drug That Could Change Everything (NASDAQ:GILD) - Seeking Alpha
Gilead (GILD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
1.24%
0.63%
자본화:
|
볼륨(24시간):